Alex Bullock is Professor of Structural and Chemical Biology at the Centre for Medicines Discovery, University of Oxford. Prior to this, he spent over 15 years at the Structural Genomics Consortium (SGC), a public-private partnership producing enabling structures, assays and chemical tools for novel drug targets, in particular protein kinases and E3 ligases. His work has defined a novel cancer mechanism of E3 ligase neofunction and identified a drug candidate for fibrodysplasia ossificans progressiva (FOP) that is currently in phase II clinical trials. He undertook doctoral training at the University of Cambridge with Sir Alan Fersht, before holding Wellcome fellowship positions with Sir Peter Ratcliffe on the VHL-HIF pathway and in the US with David Baker on Rosetta-based protein design.